SARS-CoV-2 Nucleocapsid Antigen
This biomarker measures the presence of the nucleocapsid protein of SARS-CoV-2, the virus responsible for COVID-19, in a patient's sample.
Diagnostic tool for detecting the SARS-CoV-2 nucleocapsid protein.
Key facts at a glance
- Units
- index
- Clinical utility
- diagnostic
- Result kind
- qualitative
- FDA-cleared
- Roche SARS-CoV-2 Antigen, Abbott SARS-CoV-2 Antigen
The SARS-CoV-2 Nucleocapsid Antigen test is designed to identify the presence of the nucleocapsid protein, which is a structural protein of the virus. This test is crucial for the rapid diagnosis of COVID-19, especially in the early stages of infection when the viral load is high.
The test is typically performed on respiratory samples, such as nasopharyngeal swabs or sputum. A positive result indicates active infection, while a negative result does not rule out infection and may require confirmation with other testing methods.
The reference range for this biomarker is 0–0.5 index, with values above this range indicating a positive result for the presence of the SARS-CoV-2 nucleocapsid antigen.
Frequently asked questions
What is the purpose of the SARS-CoV-2 Nucleocapsid Antigen test?
What does a positive result mean?
Sources
- 1CDC: COVID-19 TestingSource
- 2
Click any link to access the full source. PubMed Central (PMC) links provide free full-text access.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy